| Net Cash Provided by (Used in) Operating Activities |
$2,355,000,000 |
USD |
77% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$1,175,000,000 |
USD |
|
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Investing Activities |
$1,653,000,000 |
USD |
-120% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
800,000,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
286,876,206 |
shares |
-2% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0.01 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$1,877,000,000 |
USD |
498% |
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$552,000,000 |
USD |
48% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Valuation Allowance |
$119,000,000 |
USD |
-49% |
Q4 2024 |
FY 2024 |
| Deferred Tax Assets, Gross |
$485,000,000 |
USD |
6.4% |
Q4 2024 |
FY 2024 |
| Deferred Income Tax Expense (Benefit) |
$6,000,000 |
USD |
-88% |
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$225,000,000 |
USD |
-4.7% |
Q4 2024 |
FY 2024 |
| Unrecognized Tax Benefits |
$0 |
USD |
|
Q4 2024 |
FY 2024 |
| Depreciation, Depletion and Amortization |
$4,805,000,000 |
USD |
122% |
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$366,000,000 |
USD |
64% |
Q4 2024 |
FY 2024 |